登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 23 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 23
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心广州医科大学附属肿瘤医院Affiliated Cancer Hospital of Guangzhou Medical University广州医院页面
- 研究中心桂林医学院附属医院Affiliated Hospital of Guilin Medical University桂林医院页面
- 研究中心首都医科大学附属北京胸科医院Beijing Chest Hospital北京医院页面
- 研究中心滨州医学院附属医院Binzhou Medical University Hospital烟台医院页面
- 研究中心山东第一医科大学附属中心医院(济南市中心医院)Central Hospital Affiliated to Shandong First Medical University济南医院页面
- 研究中心中国人民解放军总医院Chinese PLA General Hospital北京医院页面
- 研究中心重庆大学附属肿瘤医院Chongqing University Cancer Hospital重庆医院页面
- 研究中心温州医科大学附属第一医院First Affiliated Hospital of Wenzhou Medical University温州医院页面
- 研究中心郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面
- 研究中心河北医科大学第四医院Fourth Hospital of Hebei Medical University石家庄医院页面
- 研究中心福建省肿瘤医院Fujian Cancer Hospital福州医院页面
- 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
- 研究中心吉林省肿瘤医院Jilin Cancer Hospital长春医院页面
- 研究中心临沂市人民医院Linyi People's Hospital临沂医院页面
- 研究中心中南大学湘雅二医院Second Xiangya Hospital长沙医院页面
- 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
- 研究中心山西省肿瘤医院Shanxi Cancer Hospital太原医院页面
- 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
- 研究中心浙江大学医学院附属邵逸夫医院Sir Run Run Shaw Hospital杭州医院页面
- 研究中心天津市胸科医院Tianjin Chest Hospital天津医院页面
- 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
- 研究中心襄阳市中心医院Xiangyang Central Hospital襄阳医院页面
- 研究中心云南省肿瘤医院Yunnan Cancer Hospital昆明医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06962865,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Toxicity due to prior antineoplastic therapy has not recovered to National Cancer Institute Commonly Used Criteria Terminology for Generic Adverse Events, Version 5.0, Grade 0-1;
排除标准第 10 条
Received systemic corticosteroid therapy with >10 mg/day prednisone or other immunosuppressive medications within 2 weeks before randomization;
排除标准第 15 条
ECOG PS score 0 or 1;
入选标准第 7 条
Carring 1 of 2 common EGFR mutations clearly associated with EGFR-TKI sensitivity (i.e., exon 19 deletion or L858R) and MET positivity;
入选标准第 5 条
At least one measurable lesion according to RECIST v1.1 criteria;
入选标准第 8 条
Positive test result for Human Immunodeficiency Virus (HIV) or history of Acquired Immune Deficiency Syndrome (AIDS);
排除标准第 13 条
Active hepatitis B or HCV-positive subjects;
排除标准第 14 条
Other malignant tumor within 5 years before signed the informed consent form;
排除标准第 16 条
Female subjects of childbearing potential or male subjects whose partners are of childbearing potential must agree to use effective contraception from the time of signing the informed consent form until 6 months after the last dose, during which time the female subject is not breastfeeding and the male subject avoids sperm donation.
入选标准第 11 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06962865,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntarily participate in the study and signed the ICF; Male or female, aged 18-75 years; All participants to be enrolled must be diagnosed with histopathologically or cytologically confirmed, unresectable locally advanced (stage IIIB/IIIC )or recurrent metastatic NSCLC (stage IV ) and not amendable to curative surgery or radiation as assessed by investigator; For previously locally advanced or recurrent metastatic disease not treated with systemic antitumor therapy; Carring 1 of 2 common EGFR mutations clearly associated with EGFR-TKI sensitivity (i.e., exon 19 deletion or L858R) and MET positivity; Ability to provide at least 6 sections of tumor tissue specimens for staining and testing; ECOG PS score 0 or 1; At least one measurable lesion according to RECIST v1.1 criteria; Expected survival ≥ 12 weeks; Adequate bone marrow and organ function; Female subjects of childbearing potential or male subjects whose partners are of childbearing potential must agree to use effective contraception from the time of signing the informed consent form until 6 months after the last dose, during which time the female subject is not breastfeeding and the male subject avoids sperm donation.排除标准:Exclusion Criteria:
Subjects with the presence of meningeal metastases, spinal cord compression, or active brain metastases; Received ADC or MET inhibitors; Suffering from refractory nausea and vomiting, chronic gastrointestinal disorders, inability to swallow pharmaceutical preparations, or previous major bowel resection that may prevent adequate absorption, distribution, metabolism, or excretion of oral medications; Subjects with uncontrolled tumor-related pain; Use of an investigational drug or major surgery within 4 weeks before the first dose; Received any live vaccine within 28 days prior to the first dose or plan to be vaccinated during the study; Subjects with uncontrolled or severe cardiovascular disease; Presence of clinically uncontrollable third interstitial effusion; Presence of severe lung disease, including but not limited to active tuberculosis, interstitial lung disease requiring treatment, radiation pneumonitis, etc. Toxicity due to prior antineoplastic therapy has not recovered to National Cancer Institute Commonly Used Criteria Terminology for Generic Adverse Events, Version 5.0, Grade 0-1; Persistent grade ≥2 sensory or motor neuropathy; Active infections requiring systemic IV antibiotic therapy within 7 days before the first dose, allowing routine antimicrobial prophylaxis; Positive test result for Human Immunodeficiency Virus (HIV) or history of Acquired Immune Deficiency Syndrome (AIDS); Active hepatitis B or HCV-positive subjects; Received systemic corticosteroid therapy with >10 mg/day prednisone or other immunosuppressive medications within 2 weeks before randomization; Other malignant tumor within 5 years before signed the informed consent form; Known hypersensitivity or delayed hypersensitivity to RC108, certain components of Furmonertinib or similar drugs or any contraindication to the drug; Poor compliance and unable to complete the study procedures as assessed by investigator;
引自 ClinicalTrials.gov, NCT06962865, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06962865,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。